• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

    3.150 +0.030 (+0.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 474,111
    Open 3.120
    Bid (Size) 3.150 (13)
    Ask (Size) 3.290 (3)
    Prev. Close 3.120
    Today's Range 3.000 - 3.228
    52wk Range 1.730 - 7.380
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    The market is filled with gapping stocks in Monday's session.
    The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
    Via Chartmill

    Performance

    YTD
    -29.8%
    -29.8%
    1 Month
    -15.1%
    -15.1%
    3 Month
    -31.8%
    -31.8%
    6 Month
    -47.4%
    -47.4%
    1 Year
    -25.5%
    -25.5%

    More News

    Read More
    Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga
    Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
    Via Benzinga
    Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Via Investor's Business Daily
    Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
    Via InvestorPlace

    Frequently Asked Questions

    Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
    Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
    What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
    Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
    The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
    What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
    The current price of Sagimet Biosciences Inc. - Series A Common Stock is 3.150
    When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
    The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 04/25/25 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.